Candesartan: from left ventricular hypertrophy to heart failure, a global approach

References

• Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J.26, 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Bernstein K, Celermajer D et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc. Drugs Ther.16, 149–160 (2002).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Pfeffer M, Granger C et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J. Card. Fail.5, 276–282 (1999).
   PubMedGoogle Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Kober L, TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet354, 9–12 (1999).
   PubMed Web of Science ®Google Scholar
• Jorde Up, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE mediated formation of angiotensin II in chronic heart failure. Circulation10, 844–846 (2000).
   Google Scholar
• McKelvie RS. Candesartan for the management of heart failure: more than an alternative. Expert Opin. Pharmacother.7, 1945–1956 (2006).
   PubMed Web of Science ®Google Scholar
• Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev.45, 205–251 (1993).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol.36, 281–306 (1996).
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N. Engl. J. Med.334, 1649–1654 (1996).
   PubMed Web of Science ®Google Scholar
• Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation94, 3087–3089 (1996).
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med.354, 1685–1697 (2006).
   PubMed Web of Science ®Google Scholar
• Sever P. Candesartan cilextil: a new, long-acting, effective angiotensin II Type 1 receptor blocker. J. Hum. Hypertens.1(Suppl. 2), S91–S95 (1997).
   Google Scholar
• Unger T. Pharmacology of AT1-receptor blockers. Blood Press.10(Suppl. 3), 5–10 (2001).
   Web of Science ®Google Scholar
• Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J. Hum. Hypertens.11(Suppl. 2), S9–S17 (1997).
   PubMed Web of Science ®Google Scholar
• van Lier JJ, van Heiningen PNM, Sunzel M. Absorption metabolism and excretion of candesartan and candesartan cilexetil in healthy volunteers. J. Hum. Hypertens.11(Suppl. 2), S27–S28 (1997).
   PubMed Web of Science ®Google Scholar
• McMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335, 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al, and the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee: on prevention, detection, evaluation, and treatment of high blood presure. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Levy RL, Hillman CC, Stroud WD, White PD. Transient hypertension: its significance in terms of later development of sustained hypertension and cardiovascular – renal diseases. JAMA126, 829–833 (1944).
   Google Scholar
• Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med.345, 1291–1297 (2001).
   PubMed Web of Science ®Google Scholar
• Hsia J, Margolis KL, Eaton CB et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation115, 855–860 (2007).
   PubMed Web of Science ®Google Scholar
• Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch. Intern. Med.164, 2113–2138 (2004).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke36, 1859–1863 (2005).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med. Sci. Monit.11, 403–409 (2005).
   Web of Science ®Google Scholar
• Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am. J. Hypertens.18, 980–985 (2005).
   PubMed Web of Science ®Google Scholar
• Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q.41, 155–178 (1988).
   PubMedGoogle Scholar
• Thom TJ. International mortality from heart disease: rates and trends. Int. J. Epidemiol.18(Suppl. 1), S20–S28 (1989).
   PubMedGoogle Scholar
• Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int. J. Epidemiol.23, 505–516 (1994).
   PubMed Web of Science ®Google Scholar
• Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study. J. Clin. Hypertens.3, 16–21 (2001).
   PubMedGoogle Scholar
• Vidt DG, White WB, Ridley E et al. CLAIM Study Investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J. Hum. Hypertens.15, 475–480 (2001).
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am. J. Hypertens.13, 504–511 (2000).
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am. J. Hypertens.12, 1181–1187 (1999).
   PubMed Web of Science ®Google Scholar
• Himmelmann A, Keinanen-Kiukaanniemi S, Wester A et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press.10, 43–51 (2001).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens.22, 1605–1612 (2004).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol.44, 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Mancia G, Seravalle G, Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J. Hypertens.20(Suppl. 5), S21–S27 (2002).
   PubMed Web of Science ®Google Scholar
• Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly U.S. hypertensives: analysis based on National Health And Nutrition Examination Survey (NHANES) III. Hypertension37, 869–874 (2001).
   PubMed Web of Science ®Google Scholar
• Brown DW, Giles WH, Greenlund KJ. Blood Pressure Parameters and Risk of Fatal Stroke, NHANES II Mortality Study. Am. J. Hypertens.20, 338–341 (2007).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA265, 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment in older patients with isolated systolic hypertension. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press. Suppl. 1, 27–30 (2000).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A et al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens.21, 479–485 (2007).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A et al. Blood pressure and lipid goal attainment in the hypertensive population assisted in primary care setting in Spain. J. Clin. Hypertens.9, 324–329 (2007).
   PubMedGoogle Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322, 1561–1566 (1990).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens.16, 895–899 (2003).
   PubMed Web of Science ®Google Scholar
• Mathew J, Sleight P, Lonn E et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation104, 1615–1621 (2001).
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Tanaka S, Numaguchi K et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension35, 313–318 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlof B. Left ventricular hypertrophy and angiotensin II antagonists. Am. J. Hypertens.14, 174–182 (2001).
   PubMed Web of Science ®Google Scholar
• Schneider MP, Klingbeil AU, Delles C et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension44, 61–66 (2004).
   PubMed Web of Science ®Google Scholar
• Zannad F. Preserving target-organ function with candesartan cilexetil in patients with hypertension. Blood Press. Suppl. 1, 36–39 (2000).
   PubMed Web of Science ®Google Scholar
• Isobe N, Taniguchi K, Oshima S et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ. J.66, 993–999 (2002).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens.20, 2293–2300 (2002).
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med.167, 68–73 (2007).
   PubMedGoogle Scholar
• Barrios V, Escobar C, Calderon A et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE Study. J. Renin Angiotensin Aldosterone Syst.7, 236–242 (2006).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A et al. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res. Clin. Pract.77, 492–493 (2007).
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderón A, Escobar C et al. Electrocardiographic left ventricular hypertrophy by an angiotensin receptor blocker-based regimen in daily clinical practice. The SARA study. J. Hypertens.25, 1967–1973 (2007).
   PubMed Web of Science ®Google Scholar
• Tomas JP, Moya JL, Barrios V et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J. Hypertens.24, 2109–2114 (2006).
   PubMed Web of Science ®Google Scholar
• Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. Circulation99, 1132–1137 (1999).
   PubMed Web of Science ®Google Scholar
• Barrios V, Pena G, Campuzano R, Lombera F, Peralta Y. Utility of perindopril in mild-moderate heart failure in daily clinical practice. METRICA trial. Rev. Clin. Esp.203, 3–9 (2003).
   PubMed Web of Science ®Google Scholar
• Mosser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertensive treatment trials. J. Am. Coll. Cardiol.27, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Varela A, Gonzalez JR, Basante P et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart88, 249–254 (2002).
   PubMed Web of Science ®Google Scholar
• Granger CB, Ertl G, Kuch J et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J.139, 609–617 (2000).
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Willenbrock R, Miric M et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones and clinical symptoms in patient with congestive heart failure. Am. Heart J.145, D1–D9 (2004).
   Web of Science ®Google Scholar
• Riegger GAJ, Buozo H, Petr P et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilextil. Circulation100, 2224–2230 (1999).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet362, 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet362, 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet362, 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet362, 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation110, 2618–2626 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation112, 154–235 (2005).
   PubMed Web of Science ®Google Scholar
• Cleland J. Role of angiotensin receptor blockers in the treatment of chronic heart failure: what do the clinical practice guidelines say? Rev. Esp. Cardiol. Suppl. 6, 58C–72C (2006).
   Google Scholar
• Barrios V, Calderon A, Escobar C, Blanco B, Asin E. Prevention of new-onset diabetes in patients with heart failure. Rev. Esp. Cardiol. Suppl. 6, 50C–57C (2006).
   Google Scholar
• Eguchi K, Kario K, Hoshide S, Ishikawa J, Morinari M, Shimada K. Type 2 diabetes is associated with left ventricular concentric remodelling in hypertensive patients. Am. J. Hypertens.7, 221–228 (2005).
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Ostergren JB, Gerstein HC et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation112, 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA286, 1882–1885 (2001).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Vermes E, Tardif JC, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation107, 1291–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without systolic dysfunction. J. Am. Coll. Cardiol.47, 1997–2004 (2006).
   PubMed Web of Science ®Google Scholar
• Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation107, 2926–2931 (2003).
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation100, 376–380 (1999).
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J.149, 548–557 (2005).
   PubMed Web of Science ®Google Scholar
• Barrios V, De la Figuera M, Coca A. Prevention of atrial fibrillation in hypertensive patients. Med. Clin. (Barc).128, 148–154 (2007).
   PubMed Web of Science ®Google Scholar
• Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am. Heart J.151, 86–92 (2006).
   Google Scholar
• Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J. Am. Coll. Cardiol.32, 1787–1796 (1998).
   PubMed Web of Science ®Google Scholar
• Demers C, McMurray JJ, Swedberg K et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA294, 1794–1798 (2005).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet360, 752–760 (2002).
   PubMed Web of Science ®Google Scholar
• McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol.47, 1997–2004 (2006).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar